Pre-HCT demographic and clinical characteristics of study cohort, stratified by conditioning intensity (MAC vs non-MAC)
| . | MAC (n = 515) . | Non-MAC (n = 295) . | All patients (n = 810) . | P . |
|---|---|---|---|---|
| Median age at diagnosis (range), y | 48.0 (16.7-71.3) | 64.5 (19.4-77.2) | 53.8 (16.7-77.2) | <.001 |
| Median age at HCT (range), y | 48.5 (18.1-72.6) | 65.2 (20.0-79.5) | 54.5 (18.1-79.5) | <.001 |
| Male sex, n (%) | 265 (51) | 167 (57) | 432 (53) | .16 |
| Median WBC at diagnosis (range), ×103/µL | 9.4 (0.2-297.2) | 4.4 (0.2-347.5) | 8.1 (0.2-347.5) | .0014 |
| Cytogenetics at diagnosis, n (%) | .66 | |||
| Favorable | 38 (7) | 15 (5) | 53 (7) | |
| Intermediate | 331 (64) | 193 (65) | 524 (65) | |
| Adverse | 125 (24) | 75 (25) | 200 (25) | |
| Missing | 21 (4) | 12 (4) | 33 (4) | |
| Secondary AML, n (%) | 110 (21) | 108 (37) | 218 (27) | <.001 |
| Disease status at HCT, n (%) | .61 | |||
| First remission | 389 (76) | 228 (77) | 617 (76) | |
| Second remission | 126 (24) | 67 (23) | 193 (24) | |
| Median remission duration before HCT (range), d | 98 (7-485) | 105 (11-788) | 100 (7-788) | .27 |
| Pre-HCT MRD status, n (%) | .78 | |||
| MRDneg | 411 (80) | 238 (81) | 649 (80) | |
| MRDpos | 104 (20) | 57 (19) | 161 (20) | |
| Post-HCT MRD status day +20-40, n (%) | <.001 | |||
| MRDneg | 493 (96) | 256 (87) | 749 (92) | |
| MRDpos | 22 (4) | 39 (13) | 61 (8) | |
| Early peri-HCT MRD dynamics (dichotomized), n (%) | <.001 | |||
| MRDneg/MRDneg | 408 (79) | 223 (76) | 631 (78) | |
| MRDneg/MRDpos | 3 (1) | 15 (5) | 18 (2) | |
| MRDpos/MRDneg | 85 (17) | 33 (11) | 118 (15) | |
| MRDpos/MRDpos | 19 (4) | 24 (8) | 43 (6) | |
| Early peri-HCT MRD dynamics (continuous), n (%) | <.001 | |||
| MRDneg | 408 (79) | 223 (76) | 631 (78) | |
| MRDdecreasing | 99 (19) | 44 (15) | 143 (18) | |
| MRDstable/increasing | 8 (2) | 28 (9) | 36 (4) | |
| Median time from pre-HCT MRD testing to HCT (range), days | 25 (7-68) | 21 (6-94) | 22 (6-94) | <.001 |
| Pre-HCT MRDneg | 25 (7-68) | 21 (6-94) | 23 (6-94) | .046 |
| Pre-HCT MRDpos | 23.5 (7-65) | 19 (8-42) | 22 (8-55) | |
| Recovered peripheral blood counts before HCT,* n (%) | 394 (77) | 195 (66) | 589 (73) | .0018 |
| Cytogenetics before HCT, n (%) | .48 | |||
| Normalized karyotype | 213 (41) | 106 (36) | 319 (39) | |
| Abnormal karyotype | 80 (16) | 48 (16) | 128 (16) | |
| Non-informative karyotype† | 204 (40) | 130 (44) | 334 (41) | |
| Missing | 18 (4) | 11 (4) | 29 (4) | |
| Post-HCT PB CD3 chimerism day +20-40, n (%) | <.001 | |||
| Full (≥95%) | 232 (45) | 103 (35) | 335 (41) | |
| Mixed (<95%) | 73 (14) | 157 (53) | 230 (28) | |
| Missing | 210 (41) | 35 (12) | 245 (30) | |
| HCT comorbidity index, n (%) | <.001 | |||
| 0-1 | 183 (36) | 58 (20) | 241 (30) | |
| 2-3 | 206 (40) | 110 (37) | 316 (39) | |
| ≥4 | 126 (24) | 127 (43) | 253 (31) | |
| Unrelated donor, n (%) | 344 (67) | 233 (79) | 577 (71) | <.001 |
| HLA matching, n (%) | <.001 | |||
| 10/10 HLA-identical related donor | 158 (31) | 47 (16) | 205 (25) | |
| 10/10 HLA-matched unrelated donor | 218 (42) | 167 (57) | 385 (48) | |
| 9/10 HLA-matched unrelated donor | 49 (10) | 36 (12) | 85 (10) | |
| HLA-haploidentical donor | 9 (2) | 13 (4) | 22 (3) | |
| UCB | 81 (16) | 32 (11) | 113 (14) | |
| Source of stem cells, n (%) | <.001 | |||
| PB | 372 (72) | 256 (87) | 628 (78) | |
| BM | 62 (12) | 7 (2) | 69 (9) | |
| UCB | 81 (16) | 32 (11) | 113 (14) | |
| GVHD prophylaxis, n (%) | <.001 | |||
| CNI + MMF ± sirolimus | 157 (31) | 252 (85) | 409 (50) | |
| CNI + MTX ± other | 289 (56) | 19 (6) | 308 (38) | |
| PTCy | 56 (11) | 23 (8) | 79 (10) | |
| Other | 13 (3) | 1 (0) | 14 (2) |
| . | MAC (n = 515) . | Non-MAC (n = 295) . | All patients (n = 810) . | P . |
|---|---|---|---|---|
| Median age at diagnosis (range), y | 48.0 (16.7-71.3) | 64.5 (19.4-77.2) | 53.8 (16.7-77.2) | <.001 |
| Median age at HCT (range), y | 48.5 (18.1-72.6) | 65.2 (20.0-79.5) | 54.5 (18.1-79.5) | <.001 |
| Male sex, n (%) | 265 (51) | 167 (57) | 432 (53) | .16 |
| Median WBC at diagnosis (range), ×103/µL | 9.4 (0.2-297.2) | 4.4 (0.2-347.5) | 8.1 (0.2-347.5) | .0014 |
| Cytogenetics at diagnosis, n (%) | .66 | |||
| Favorable | 38 (7) | 15 (5) | 53 (7) | |
| Intermediate | 331 (64) | 193 (65) | 524 (65) | |
| Adverse | 125 (24) | 75 (25) | 200 (25) | |
| Missing | 21 (4) | 12 (4) | 33 (4) | |
| Secondary AML, n (%) | 110 (21) | 108 (37) | 218 (27) | <.001 |
| Disease status at HCT, n (%) | .61 | |||
| First remission | 389 (76) | 228 (77) | 617 (76) | |
| Second remission | 126 (24) | 67 (23) | 193 (24) | |
| Median remission duration before HCT (range), d | 98 (7-485) | 105 (11-788) | 100 (7-788) | .27 |
| Pre-HCT MRD status, n (%) | .78 | |||
| MRDneg | 411 (80) | 238 (81) | 649 (80) | |
| MRDpos | 104 (20) | 57 (19) | 161 (20) | |
| Post-HCT MRD status day +20-40, n (%) | <.001 | |||
| MRDneg | 493 (96) | 256 (87) | 749 (92) | |
| MRDpos | 22 (4) | 39 (13) | 61 (8) | |
| Early peri-HCT MRD dynamics (dichotomized), n (%) | <.001 | |||
| MRDneg/MRDneg | 408 (79) | 223 (76) | 631 (78) | |
| MRDneg/MRDpos | 3 (1) | 15 (5) | 18 (2) | |
| MRDpos/MRDneg | 85 (17) | 33 (11) | 118 (15) | |
| MRDpos/MRDpos | 19 (4) | 24 (8) | 43 (6) | |
| Early peri-HCT MRD dynamics (continuous), n (%) | <.001 | |||
| MRDneg | 408 (79) | 223 (76) | 631 (78) | |
| MRDdecreasing | 99 (19) | 44 (15) | 143 (18) | |
| MRDstable/increasing | 8 (2) | 28 (9) | 36 (4) | |
| Median time from pre-HCT MRD testing to HCT (range), days | 25 (7-68) | 21 (6-94) | 22 (6-94) | <.001 |
| Pre-HCT MRDneg | 25 (7-68) | 21 (6-94) | 23 (6-94) | .046 |
| Pre-HCT MRDpos | 23.5 (7-65) | 19 (8-42) | 22 (8-55) | |
| Recovered peripheral blood counts before HCT,* n (%) | 394 (77) | 195 (66) | 589 (73) | .0018 |
| Cytogenetics before HCT, n (%) | .48 | |||
| Normalized karyotype | 213 (41) | 106 (36) | 319 (39) | |
| Abnormal karyotype | 80 (16) | 48 (16) | 128 (16) | |
| Non-informative karyotype† | 204 (40) | 130 (44) | 334 (41) | |
| Missing | 18 (4) | 11 (4) | 29 (4) | |
| Post-HCT PB CD3 chimerism day +20-40, n (%) | <.001 | |||
| Full (≥95%) | 232 (45) | 103 (35) | 335 (41) | |
| Mixed (<95%) | 73 (14) | 157 (53) | 230 (28) | |
| Missing | 210 (41) | 35 (12) | 245 (30) | |
| HCT comorbidity index, n (%) | <.001 | |||
| 0-1 | 183 (36) | 58 (20) | 241 (30) | |
| 2-3 | 206 (40) | 110 (37) | 316 (39) | |
| ≥4 | 126 (24) | 127 (43) | 253 (31) | |
| Unrelated donor, n (%) | 344 (67) | 233 (79) | 577 (71) | <.001 |
| HLA matching, n (%) | <.001 | |||
| 10/10 HLA-identical related donor | 158 (31) | 47 (16) | 205 (25) | |
| 10/10 HLA-matched unrelated donor | 218 (42) | 167 (57) | 385 (48) | |
| 9/10 HLA-matched unrelated donor | 49 (10) | 36 (12) | 85 (10) | |
| HLA-haploidentical donor | 9 (2) | 13 (4) | 22 (3) | |
| UCB | 81 (16) | 32 (11) | 113 (14) | |
| Source of stem cells, n (%) | <.001 | |||
| PB | 372 (72) | 256 (87) | 628 (78) | |
| BM | 62 (12) | 7 (2) | 69 (9) | |
| UCB | 81 (16) | 32 (11) | 113 (14) | |
| GVHD prophylaxis, n (%) | <.001 | |||
| CNI + MMF ± sirolimus | 157 (31) | 252 (85) | 409 (50) | |
| CNI + MTX ± other | 289 (56) | 19 (6) | 308 (38) | |
| PTCy | 56 (11) | 23 (8) | 79 (10) | |
| Other | 13 (3) | 1 (0) | 14 (2) |
ANC, absolute neutrophil count; BM, bone marrow; CNI, calcineurin inhibitor; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil; MTX, methotrexate; PB, peripheral blood; PTCy, posttransplantation cyclophosphamide; UCB, umbilical cord blood.
ANC ≥ 1000/µL and platelets ≥ 100 000/µL.
Normal cytogenetics in patient with cytogenetically normal AML or missing cytogenetics at diagnosis.